A multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma (RCC)

Trial Profile

A multi-national, multi-center, randomized Phase 2/3 study of Pazopanib plus Abexinostat versus Pazopanib monotherapy in patients with locally advanced or metastatic renal cell carcinoma (RCC)

Planning
Phase of Trial: Phase II/III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Abexinostat (Primary) ; Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PAX study
  • Most Recent Events

    • 31 May 2017 New trial record
    • 22 May 2017 According to a Xynomic Phatrmaceuicals media release, the company will work with regulatory agencies to plan this trial which could accelerate approval of Abexinostat for solid tumours.
    • 22 May 2017 According to a Xynomic Phatrmaceuicals media release, the company has entered into a strategic partnership with the University of California San Francisco (UCSF) to conduct this trial. This trial will be led by Pamela Munster and Rahul Aggarwal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top